CEO Jon Congleton was paid $5,544,727 in fiscal year 2025, ↑ up 2.3% from fiscal year 2024 (SEC filing 0001933414-26-000069 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$5,544,727 ↑ Jon Congleton total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
You have just read Mineralys Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper MLYS reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
MLYS's next annual pay disclosure, estimated April 8, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jon Congleton | $636,500 | $0 | $0 | $4,435,626 | $472,601 | $0 | $0 | $5,544,727 |
| President and Chief Executive Officer | ||||||||
| David Rodman | 533,000 | 25,000 | 0 | 1,322,906 | 323,798 | 0 | 0 | 2,204,704 |
| Chief Medical Officer | ||||||||
| Adam Levy | 532,000 | 25,000 | 0 | 1,322,906 | 323,190 | 0 | 0 | 2,203,096 |
| Chief Financial Officer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jon Congleton | $5,544,727 | $5,420,868 | $5,355,257 | ↑ +123,859 |
| David Rodman | 2,204,704 | 2,877,749 | 2,347,407 | ↓ −673,045 |
| Adam Levy | 2,203,096 | 2,849,200 | 2,189,381 | ↓ −646,104 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
Each company listed discloses MLYS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named MLYS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alexander Gold, M.D | Independent Director | $305,276 |
| Brian Taylor Slingsby, M.D., Ph.D., M.P.H | Independent Director | $247,043 |
| Daphne Karydas | Independent Director | $307,043 |
| Derek DiRocco, Ph.D | Independent Director | $304,543 |
| Glenn P. Sblendorio | Chair of the Board | $331,310 |
| Srinivas Akkaraju, M.D., Ph.D | Independent Director | $292,927 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Adam Levy | RSU | 6,524 | — | $236,756 |
| Adam Levy | Option | 85,968 | 14.25 | — |
| Adam Levy | Option | 4,373 | 15.44 | — |
| Jon Congleton | RSU | 95,881 | — | 3,479,521 |
| Adam Levy | RSU | 6,526 | — | 236,829 |
| Jon Congleton | Option | 72,931 | 16 | — |
| Jon Congleton | Option | 31,188 | 15.44 | — |
| Jon Congleton | Option | 230,209 | 14.25 | — |
| Jon Congleton | Option | 451,251 | 10.2 | — |
| Adam Levy | Option | 19,410 | 16 | — |
| Adam Levy | Option | 129,319 | 10.2 | — |
| David Rodman | Option | 30,388 | 16 | — |
| David Rodman | Option | 6,250 | 15.44 | — |
| David Rodman | Option | 108,334 | 14.25 | — |
| David Rodman | Option | 134,584 | 10.2 | — |
The company's compensation program is designed to provide appropriate incentives to executives to achieve defined annual corporate goals and to reward individual achievement, while equity-based incentive awards are designed to align the interests of the company and its stockholders with those of its employees.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | — | — | — | — | — |
| 2025 | 2025-05-22 | — | — | — | — | — |
| 2024 | 2024-05-22 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-21 | —a |
| 2025 | 2025-05-22 | —b |
| 2024 | 2024-05-22 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Glenn P. SblendorioIndependent · Board Chair · Compensation · Audit | $84,267 | — | $247,043 | — | — | $331,310 |
| Daphne KarydasIndependent · Audit (Chair) | 60,000 | — | 247,043 | — | — | 307,043 |
| Alexander Gold, M.DIndependent · Compensation · Nominating and Corporate Governance | 58,233 | — | 247,043 | — | — | 305,276 |
| Derek DiRocco, Ph.DIndependent · Compensation · Audit | 57,500 | — | 247,043 | — | — | 304,543 |
| Srinivas Akkaraju, M.D., Ph.DIndependent · Compensation · Nominating and Corporate Governance | 45,884 | — | 247,043 | — | — | 292,927 |
| Brian Taylor Slingsby, M.D., Ph.D., M.P.HIndependent · Compensation · Nominating and Corporate Governance (Chair) | 0 | — | 247,043 | — | — | 247,043 |
| Jon CongletonEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $305,884 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $305,884 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Mineralys Therapeutics | 2025 | Jon Congleton | $636,500 | $0 | $4,435,626 | $472,601 | $5,544,727 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Jon Congleton | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Executive Compensation”. As printed: 5,544,727. Filing ↗machine: r2 · c48 · span 235758–235767 |
| 2 | Section 01, David Rodman | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Executive Compensation”. As printed: 2,204,704. Filing ↗machine: r6 · c48 · span 246847–246856 |
| 3 | Section 01, Adam Levy | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Executive Compensation”. As printed: 2,203,096. Filing ↗machine: r4 · c48 · span 241311–241320 |
| 4 | Section 08, Glenn P. Sblendorio | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 331,310. Filing ↗machine: span 366728–367110 |
| 5 | Section 08, Daphne Karydas | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 307,043. Filing ↗machine: span 365091–365473 |
| 6 | Section 08, Alexander Gold, M.D | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 305,276. Filing ↗machine: span 363459–363841 |
| 7 | Section 08, Derek DiRocco, Ph.D | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 304,543. Filing ↗machine: span 361821–362203 |
| 8 | Section 08, Srinivas Akkaraju, M.D., Ph.D | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 292,927. Filing ↗machine: span 360131–360539 |
| 9 | Section 08, Brian Taylor Slingsby, M.D., Ph.D., M.P.H | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 247,043. Filing ↗machine: span 367906–368288 |
| 10 | Section 08, Jon Congleton | DEF 14A | 2026-04-08 | 0001933414-26-000069 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 06, 2026 vote | Form 8-K | 2026-05-22 | 0001933414-26-000090 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 12 | Section 06, 2025 vote | Form 8-K | 2025-05-22 | 0001933414-25-000064 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 13 | Section 06, 2024 vote | Form 8-K | 2024-05-22 | 0001933414-24-000017 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 15 | Section 09b board cost (computed) | Computed | — | — | Cash 305,884 + equity 0 + all other 0 = 305,884, summed across the director compensation table rows.machine: formula: Σ = 305,884 |
| 16 | Mineralys Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-08 | 0001933414-26-000069 | CEO total compensation as printed in Mineralys Therapeutics's own proxy. As printed: 5,544,727. Filing ↗machine: r2 · c48 · span 235758–235767 |